Trial Profile
An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma [Studio internazionale randomizzato, in doppio cieco, controllato, di fase II con Rindopepimut/GM-CSF e temozolomide in terapia adiuvante in pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente.]
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2013
Price :
$35
*
At a glance
- Drugs Rindopepimut (Primary) ; Keyhole limpet haemocyanin; Sargramostim; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms Irradiance
- 12 Aug 2013 New trial record